Today: 14 May 2026
Browse Category

Pharmaceuticals 1 January 2026 - 3 January 2026

Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Eli Lilly shares rose 0.5% to $1,080.36 in after-hours trading Friday after a volatile session. The move follows sector-wide drug price changes and renewed Washington scrutiny, with manufacturers planning 2026 list-price hikes. Investors are watching upcoming U.S. jobs and inflation data, as well as Lilly’s Jan. 13 conference appearance ahead of its Feb. 4 earnings report.
3 January 2026
··
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie shares rose 0.2% to $228.95 after Ironwood Pharmaceuticals, its Linzess partner, raised 2026 U.S. net sales guidance and cut the drug’s list price effective Jan. 1. Ironwood shares jumped 29.5%. Ironwood now expects 2026 Linzess U.S. net sales of $1.125–$1.175 billion, up from 2025’s $860–$890 million forecast. Wall Street trading was muted as investors awaited U.S. labor data and watched for broader drug pricing moves.
2 January 2026
···
Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer shares rose 0.8% to $25.09 Friday amid renewed focus on U.S. drug pricing after reports of 2026 list-price hikes, including a 15% increase for its COVID-19 vaccine. A Reuters report said Pfizer will lead price increases on about 80 drugs, though most hikes are under 10%. Investors await Pfizer’s next quarterly update on February 3. Trading volume reached about 20.7 million shares.
2 January 2026
··
Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

Pfizer shares fell 0.4% to $24.90 in premarket trading Friday after Reuters reported the company plans to raise U.S. list prices on about 80 medicines in 2026, including a 15% hike for COVID-19 vaccine Comirnaty. The moves come as drugmakers face pressure from the Trump administration to lower prices and as investors await Pfizer’s February 3 results update.
2 January 2026
··
AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

Axsome Therapeutics shares surged 22.9% to $182.64 on Dec. 31 after the FDA accepted its AXS-05 filing for Alzheimer’s disease agitation and set an April 30, 2026 target action date. The company also said it plans to submit an NDA for AXS-12 in narcolepsy in January, following supportive FDA meeting minutes. Trading volume reached 3.1 million shares.
2 January 2026
·
Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, with a median increase of about 4%, according to 3 Axis Advisors. List prices for about nine drugs will drop, including a more than 40% cut for Jardiance after Medicare negotiations. Eli Lilly faces price pressure in both the U.S. and China, where its diabetes drug Mounjaro will also get cheaper from Jan. 1.
1 January 2026
··
Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

Corcept Therapeutics shares plunged 50.4% to $34.80 on Dec. 31 after the FDA declined to approve relacorilant for hypercortisolism-related hypertension, citing insufficient evidence of effectiveness. Wolfe Research downgraded the stock to Underperform with a $30 target. Trading was briefly halted before resuming with heavy volume. The FDA set a separate July 2026 decision date for relacorilant in ovarian cancer.
1 January 2026
··
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics shares closed 2025 up 3.5% at $63.54 after FDA cleared Myqorzo for obstructive hypertrophic cardiomyopathy. The drug, set to launch in January under a REMS program and boxed warning, will compete with Bristol Myers Squibb’s Camzyos. Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 each on Dec. 29 under a pre-arranged plan. U.S. markets reopen Friday after the New Year’s holiday.
1 January 2026
····
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer shares slipped 0.4% to $24.90 after hours following a report the company will raise U.S. list prices on about 80 medicines in 2026, including a 15% hike for its COVID vaccine Comirnaty. Most Pfizer increases are under 10%. U.S. stock markets were closed Thursday for New Year’s Day. Investors await Pfizer’s Feb. 3 results and 2026 outlook.
1 January 2026
···
Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Outlook Therapeutics shares dropped from $1.58 to about $0.58 after hours on Dec. 31 after the FDA issued a third complete response letter declining approval for its Lytenava wet-AMD drug. The FDA said more confirmatory efficacy evidence is needed but did not specify requirements. The drug is already approved in the EU and UK. U.S. markets reopen Friday after the New Year’s holiday.
1 January 2026
··
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT

Corcept Therapeutics shares fell 50.4% to $34.80 after the FDA declined to approve relacorilant for Cushing’s-related hypertension, citing a need for more evidence of effectiveness. The company plans to meet with the agency to discuss next steps. Wolfe Research downgraded the stock and removed projected sales for the indication. Trading volume reached about 20.16 million shares.
1 January 2026
··
Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson stock ends 2025 steady as Halda deal closes and Barclays hikes target

Johnson & Johnson closed its $3.05 billion acquisition of Halda Therapeutics, saying the deal will cut adjusted EPS by $0.20 between late 2025 and 2026. JNJ shares edged up 0.02% to $206.95 as the S&P 500 fell 0.74% on the year’s final trading day. Barclays raised its price target to $217, maintaining an Equal Weight rating. The company will discuss its 2026 outlook on Jan. 21.
1 January 2026
··
1 … 20 21 22 23 24 … 40

Stock Market Today

  • ABNB and BKNG Outperform Hyatt Hotels in Valuation and Growth Metrics
    May 14, 2026, 4:13 AM EDT. In the Hotels, Resorts & Cruise Lines industry, Airbnb (ABNB) and Booking Holdings (BKNG) show lower valuation and higher revenue and operating income growth compared to Hyatt Hotels (H). ABNB and BKNG trade at price-to-operating-income ratios (P/OpInc) of 30.7x and 12.9x respectively, versus Hyatt's 32.7x, while delivering stronger latest twelve months (LTM) and three-year average growth. Hyatt's LTM operating income growth stands at -0.4%, lagging ABNB's 4.1% and BKNG's 21.3%. Market capitalizations also differ notably, with Hyatt at $15.8 billion, ABNB at $79.5 billion, and BKNG at $122.5 billion. Despite strong growth elsewhere, Hyatt's higher valuation and weaker recent income growth suggest investors may favor ABNB and BKNG stocks. Multi-factor analysis remains essential before investment decisions.

Latest articles

Nvidia’s China H200 Chip Door Just Opened. The Money Still Isn’t Moving

Nvidia’s China H200 Chip Door Just Opened. The Money Still Isn’t Moving

14 May 2026
The U.S. has approved Nvidia to sell H200 AI chips to about 10 Chinese firms, including Alibaba and Tencent, but no shipments have occurred as Chinese buyers hold back under Beijing’s guidance. Nvidia CEO Jensen Huang is in Beijing with President Trump’s delegation ahead of the company’s May 20 earnings report. Lenovo confirmed it is cleared to distribute the chips in China.
Nokia Stock Surges Again as Cisco’s AI Orders Put New Heat Under the Network Trade

Nokia Stock Surges Again as Cisco’s AI Orders Put New Heat Under the Network Trade

14 May 2026
Nokia shares jumped about 10% in Helsinki Thursday, extending gains after Cisco reported $5.3 billion in AI infrastructure orders and raised its full-year outlook. Nokia launched new agentic AI tools for broadband networks and named Siemens executive Emma Falck as president of Mobile Infrastructure. The stock approached levels last seen 16 years ago.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 14.05.2026

14 May 2026
LIVEMarkets rolling coverageStarted: May 14, 2026, 12:00 AM EDTUpdated: May 14, 2026, 4:21 AM EDT ABNB and BKNG Outperform Hyatt Hotels in Valuation and Growth Metrics May 14, 2026, 4:13 AM EDT. In the Hotels, Resorts & Cruise Lines industry, Airbnb (ABNB) and Booking Holdings (BKNG) show **lower valuation** and **higher revenue and operating income growth** compared to Hyatt Hotels (H). ABNB and BKNG trade at price-to-operating-income ratios (P/OpInc) of 30.7x and 12.9x respectively, versus Hyatt's 32.7x, while delivering stronger latest twelve months (LTM) and three-year average growth. Hyatt's LTM operating income growth stands at -0.4%, lagging ABNB's 4.1% and
Go toTop